Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer

Meng Su¹
Ya Gao¹
XuXue Ye¹
QingYu Zhou¹
LiHao Zhao¹
Xiaona Cai²
Didi Chen¹
Huafang Su¹
Xiaohua Zhang¹,³,*
Congying Xie¹,*

¹Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China; ²Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China; ³Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China

*These authors contributed equally to this work

Purpose: Apatinib is effective and safe for several advanced or metastatic cancers, but its therapeutic value in cervical cancer is still unknown. The aim of the study was to assess the therapeutic value of apatinib in patients with chemo-refractory advanced cervical cancer.

Patients and methods: This was a retrospective study of patients with advanced cervical cancer treated with apatinib between April 2015 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Patients had to have failed at least 2 lines of chemotherapy prior to receiving apatinib. The clinical tumor response was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events were evaluated.

Results: Twenty-five patients were included in this study. The median PFS was 5.8 months (95% CI, 4.65–6.95), and the median OS was 12.2 months (95% CI, 8.99–15.41). ORR was 48% and DCR was 96%. Complete response was not observed. The most common adverse events in this study (all grades) were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%).

Conclusion: Apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer.

Keywords: cervix carcinoma, YN968D1, antiangiogenesis drug, efficacy, safety

Introduction

Cervical cancer is a growing threat to women’s health and remains a main cause of cancer death among women around the world.¹ Indeed, cervical cancer was estimated to account for more than 12,000 new cancer cases and 4000 deaths in the United States in 2015.¹ Cervical cancer is the seventh most common cancer among women worldwide.²

Patients with cervical cancer often have a favorable response to radical surgery followed by adjuvant therapy (including platinum-based chemotherapy and radiotherapy).³,⁵ Nevertheless, some patients will develop recurrent tumors or will be initially diagnosed as advanced disease. Apart from platinum-resistant cancers, cisplatin or carboplatin plus paclitaxel is an appropriate chemotherapy regimen for these recurrent or advanced tumors.⁶ Despite its effectiveness, the median progression-free survival (PFS) is only 5.3 months.⁶ Furthermore, there is no standard regimen for second- and third-line chemotherapy. After failure of multiple lines of chemotherapy, targeted therapy can be an appropriate choice for
advanced cervical cancer.\textsuperscript{7,8} Antiangiogenesis therapy is a common choice for these advanced patients.

Bevacizumab is a monoclonal antibody against the vascular endothelial growth factor (VEGF) and has been widely used against chemotherapy-refractory advanced cervical cancer. When adding bevacizumab to chemotherapy, overall survival (OS), PFS, and tumor response can be improved in cervical cancer patients.\textsuperscript{9} Nevertheless, its efficacy is still unsatisfactory. Other VEGF receptor (VEGFR) tyrosine kinase inhibitors (including pazopanib, lapatinib, sunitinib) have been seldom used and showed poor efficacy in patients with cervical cancer.\textsuperscript{10,11}

Apatinib belongs to the first generation of oral antiangiogenesis drug and selectively inhibits VEGFR-2, leading to decreased vascular endothelial cell proliferation and migration, and tumor microvascular density.\textsuperscript{12} A Phase II trial in advanced or metastatic gastric carcinoma showed that apatinib could improve OS and PFS compared with placebo,\textsuperscript{13} which was further confirmed by a Phase III trial.\textsuperscript{14} Several papers indicated that apatinib was an appropriate choice for chemo-refractory malignancies.\textsuperscript{15–17}

Although some papers have demonstrated that apatinib was effective and safe for advanced or metastatic gastric cancer, breast cancer, ovarian cancer, lung cancer, and liver cancer;\textsuperscript{13,14,18–22} doubts still exist about whether it is an appropriate choice for patients with advanced cervical cancer. Therefore, the aim of this retrospective study was to assess the efficacy and safety of apatinib in advanced cervical cancer patients with ≥2 lines of chemotherapy failure. Although retrospective, this study could suggest novel treatment approach for advanced cervical cancer.

**Materials And Methods**

**Study Design And Patients**

This was a retrospective study of patients with advanced cervical cancer treated with apatinib between April 2015 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Written informed consents were obtained from all the patients before apatinib treatment.

**Apatinib Treatment**

Apatinib (YN968D1, Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) orally administered at an initial dose of 500 mg once daily; if the patient had a body surface <1.25 m\(^2\), the starting dose was 250 mg daily. Then, the dose was adjusted according to adverse events and performance status between 250 mg and 850 mg daily. Dose reduction of apatinib resulting from grade 3–4 adverse events was allowed, but was not lower than 250 mg daily. If no grade 2–4 adverse event was observed, the dose of apatinib could be increased from 250 mg to 425 mg or 500 mg daily, or 500 mg to 675 mg or 850 mg daily. One treatment cycle was defined as 28 days (4 weeks). All eligible patients received continuous treatment until disease progression, death, or intolerable toxicity (as determined by their physicians).

**Assessment Of Clinical Efficacy**

PFS was defined as the duration from starting apatinib to disease progression or death. OS was defined as the duration from starting apatinib to death. The objective response rate (ORR) included complete response (CR) and partial response (PR). The disease control rate (DCR) included CR, PR, and stable disease (SD).

The clinical tumor response, determined by assessing the degree of tumor shrinkage, was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Magnetic resonance imaging (MRI) and/or computed tomography (CT) were performed before and during oral apatinib. The tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.\textsuperscript{23} RECIST adopts a unidimensional measurement for solid tumors. CR was defined as the disappearance of all target lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, without new lesions. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameters of target lesions and ≥5 mm increase above nadir, or the appearance of new lesions. Patients who did not meet the criteria for PR or PD were classified as having SD.

**Clinical Assessment For Toxicity**

Toxicity was analyzed by assessing the incidence of adverse events. The adverse event grades were defined
according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3.0 (CTCAE v3.0).²⁴

Statistical Analysis
Descriptive statistics were used. Continuous data were presented as mean ± standard deviation or median (range). Categorical data were presented as frequencies. Survival analyses, including OS and PFS, were performed using the Kaplan–Meier method. Data management was performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism, Version 8.0 (GraphPad Software Inc., San Diego, CA, USA).

Results
Characteristics Of The Patients
A total of 32 patients with cervical cancer received apatinib alone during the study period, but three were excluded due to treatment duration <1 month, four were excluded due to being lost to follow up. Finally, 25 patients were included. The characteristics of the patients are shown in Table 1. Six patients experienced dose adjustment during treatment (Table 2). After dose adjustment, 17 patients (68%) received ≥500 mg/day of apatinib.

Clinical Efficacy
The survival time and tumor response are presented in Table 3. The median PFS was 5.8 months (95% CI, 4.65–6.95), and the median OS was 12.2 months (95% CI, 8.99–15.41) (Figure 1). ORR was 48% and DCR was 96%. Of note, CR was not observed. Decrease of tumor size occurred in 21 patients (84%) (Figure 2).

Adverse Events
Table 4 presents the treatment-related adverse events that were observed among all 25 patients. Most adverse events were mild and manageable and there was no adverse event associated with death. The grade 3/4 treatment-related adverse events were hand-foot syndrome (n=3, 12%), mouth mucositis (n=1, 4%), and thrombocytopenia (n=1, 4%). The most common adverse events in this study (all grades) were hand-foot syndrome (n=12, 48%), hypertension (n=5, 20%), and mouth mucositis (n=5, 20%). Dose reduction occurred in five patients due to adverse events. One patient refused oral apatinib after 3 months of treatment, due to grade 4 hand-foot syndrome.

| Table 1 Patient Characteristics |
|-------------------------------|
| Characteristics               | n=25 |
| **Age (years)**               |      |
| Median                        | 55   |
| Range                         | 26–73|
| **ECOG PS (%)**               |      |
| 0                             | 5 (20) |
| 1                             | 16 (64) |
| 2                             | 4 (16)  |
| **Stage* at initial diagnosis (%)** |      |
| I                             | 12 (48) |
| II                            | 3 (12)  |
| III                           | 7 (28)  |
| IV                            | 3 (12)  |
| **Site of metastatic disease (%)** |      |
| Nodes                         | 10 (40) |
| Lung                          | 13 (52) |
| Liver                         | 4 (16)  |
| Brain                         | 1 (4)   |
| Pelvic cavity                 | 7 (28)  |
| Bone                          | 9 (36)  |
| Soft tissue                   | 1 (4)   |
| **No. of sites of metastatic disease (%)** |      |
| 1                             | 11 (44) |
| 2                             | 9 (36)  |
| 3                             | 4 (16)  |
| 4                             | 1 (4)   |
| **Histological differentiation (%)** |      |
| Undifferentiated              | 2 (8)   |
| Poorly differentiated         | 6 (24)  |
| Moderately differentiated     | 17 (68) |
| **Lines of prior chemotherapy (%)** |      |
| 2 lines                       | 15 (60) |
| 3 lines                       | 6 (24)  |
| 4 lines                       | 4 (16)  |
| **Prior radiation (%)**       |      |
| Yes                           | 17 (68) |
| No                            | 8 (32)  |
| **Prior radical surgery (%)** |      |
| Yes                           | 19 (76) |
| No                            | 6 (24)  |

Note: *International Federation of Gynecology and Obstetrics 2018 staging.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.

Typical Case
A 43-year-old female patient with advanced cervical cancer and with failure to 3 lines of chemotherapy received apatinib at 500 mg daily in September 2015. From September 2015 to June 2016, the longest diameter of the
retroperitoneal lesion decreased from 33 to 23 mm and lung metastases also shrunk significantly or disappeared (Figure 3), which was defined as PR. Serum squamous cell carcinoma (SCC) antigen decreased from 52.9 to 24.8 μg/L. The patient only suffered from grade 2 hand-foot syndrome. Disease progression occurred on November 2016 and serum SCC antigen increased to 65.7 μg/L. Then, the patient stopped to use apatinib.

**Discussion**

Cervical cancer is a common female malignancy. The early-staged patients will have favorable outcomes,\(^3\)–\(^5\) while advanced ones will have poor prognosis.\(^25\) Antiangiogenesis therapy is common for advanced cervical cancer, but with limited efficacy.\(^9\)–\(^11\) Therefore, to find a new, effective and safe targeted drug for these patients is a matter of urgency for improving treatment outcomes.

VEGF and VEGFR-2 play an essential role in tumor angiogenesis.\(^26\) Apatinib (formerly known as YN968D1) targets VEGFR-2, RET, platelet-derived growth factor-β

**Table 2** Dose Adjustment

| Initial Dose (%) | n=25 |
|------------------|------|
| 250 mg daily     | 3 (12) |
| 500 mg daily     | 22 (88) |

| Dose adjustment (%) | |
|---------------------|------|
| Yes                 | Increase | 1 (4) |
|                     | Decrease | 5 (20) |
| No                  |         | 19 (76) |

**Table 3** Efficacy Of Apatinib In Patients With Cervical Cancer

|               | n=25 | 95% CI         |
|---------------|------|----------------|
| Median PFS (months) | 5.8  | 4.65–6.95     |
| Median OS (months)  | 12.2 | 8.99–15.41    |
| Tumor response    |      |               |
| PR (%)            | 12 (48) |               |
| SD (%)            | 12 (48) |               |
| PD (%)            | 1 (4)  |               |
| ORR               | 48%   |               |
| DCR               | 96%   |               |

Abbreviations: PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; CI, confidence interval.

**Figure 1** Kaplan–Meier curve of progression-free survival (A) and overall survival (B). Red-dotted lines represent 95% confidence intervals (CIs).
According to in vitro experiments, apatinib is an even more selective inhibitor of VEGFR-2 than sunitinib, with an IC50 of 0.001 μM and 0.005 μM, respectively. Apatinib can effectively inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells, can block the budding of rat aortic ring, and can inhibit the growth of several established human tumor xenograft models with little toxicity. Previous studies reported that apatinib could reverse ATP-binding cassette transporter (ABC) subfamily B member 1 (MDR1/P-glycoprotein) and ABC subfamily G member 2 (BCRP)-mediated multidrug resistance, which leads to potential usefulness of combining apatinib with other chemotherapy drugs.

In a Phase I trial, apatinib has shown encouraging antitumor activity (18.9% of PR and 64.9% of SD) and a manageable toxicity profile in patients with advanced solid malignancies, including gastric, colorectal, lung, and breast cancers. The efficacy and safety of apatinib were further confirmed in advanced or metastatic gastric cancer, breast cancer, ovarian cancer, lung cancer, and liver cancer by recent clinical trials. These data suggest that apatinib was a favorable choice as rescue therapy for the advanced patients with ≥2 lines of chemotherapy failure. Nevertheless, the therapeutic value of apatinib in cervical cancer is still unknown. In the present study, apatinib showed median PFS, median OS, ORR, and DCR of 5.8 months, 12.2 months, 48%, and 96%, respectively, which were not worse than the data observed in other malignancies.

The efficacy and safety of bevacizumab have been proven by several clinical trials. In a Phase II trial, patients with persistent or recurrent cervical cancer treated with bevacizumab, achieved median PFS of 3.4 months, median OS of 7.3 months, and ORR of 11% (no CR and five PR, total 46 patients), respectively. Patients with platinum-resistant cervical cancer can also benefit from bevacizumab.

### Table 4 Adverse Events Based On Treatment

|                  | n=25 |        | Grade 3/4 |
|------------------|------|--------|-----------|
| Hypertension (%) | 5 (20) | 0      |           |
| Proteinuria (%)  | 4 (16) | 0      |           |
| Hand-foot syndrome (%) | 12 (48) | 3 (12) |           |
| Mouth mucositis (%) | 5 (20) | 1 (4)  |           |
| Bleeding (%)     | 1 (4)  | 0      |           |
| Fatigue (%)      | 3 (12) | 0      |           |
| Abdominal pain (%) | 1 (4)  | 0      |           |
| Decreased appetite (%) | 2 (8)  | 0      |           |
| Thrombocytopenia (%) | 1 (4)  | 1 (4)  |           |

**Figure 3 (A1-2)** Computed tomography (CT) scan before apatinib treatment (September 2015). **(B1-2)** CT scan after 1 month of apatinib treatment (October 2015). **(C1-2)** CT scan after 10 months of apatinib treatment (June 2016). The longest diameters of the retroperitoneal lesions (red arrows) were 33 mm (**A1**), 25 mm (**B1**), and 23 mm (**C1**). From **A2 to C2**, lung metastases (red arrows) shrunk significantly or disappeared.
Other VEGFR tyrosine kinase inhibitors (including pazopanib, lapatinib, and sunitinib) were seldom used in cervical cancer. In clinical trials of advanced or recurrent cervical cancer, median PFS of pazopanib, lapatinib, and sunitinib were 18.1 weeks, 17.1 weeks, and 3.5 months, respectively; median OS of pazopanib and lapatinib were 50.7 weeks and 39.1 weeks, respectively; ORRs of pazopanib, lapatinib, and sunitinib were 9.5%, 5.1%, and 0%, respectively; and DCRs of pazopanib, lapatinib, and sunitinib were 52.7%, 48.7%, and 84.2%, respectively.\textsuperscript{10,11} The comparison between apatinib and other antiangiogenesis drugs is shown in Table 5.

The most common treatment-related adverse events of apatinib in this study were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%), which were similar to those reported in other malignancies.\textsuperscript{14,18,19,22} During oral apatinib treatment, five patients received dose reductions and one patient discontinued treatment due to treatment-related adverse events. Other patients experienced mild and manageable adverse events.

The present study has two limitations. First, the number of patients was small and clinical significance was limited. The next step will be to further expand the number of patients. Secondly, this was a retrospective study. A multicenter randomized controlled study focusing on this issue is warranted.

**Conclusion**

In this study, apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer. The feasibility of apatinib combined with chemotherapy in advanced cervical cancer should be further confirmed in future studies.

**Abbreviations**

PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate; VEGF, vascular endothelial growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; MRI, magnetic resonance imaging; CT, computed tomography; RECIST, Response Evaluation Criteria in Solid Tumors; CTCAE, Common Terminology Criteria for Adverse Events; PD, progressive disease; SCC, squamous cell carcinoma; PDGFR-\(\beta\), platelet-derived growth factor-\(\beta\); ABC, ATP-binding cassette transporter.

**Table 5 Comparison Between Apatinib And Other Antiangiogenesis Drugs**

| Lines Of Prior Chemotherapy | n  | mPFS (Months) | mOS (Months) | ORR (%) | DCR (%) | Reference |
|-----------------------------|----|--------------|--------------|---------|---------|-----------|
| Apatinib \(\geq 2\) lines   | 25 | 5.8          | 12.2         | 48      | 96      | Present study |
| Bevacizumab 1 or 2 lines    | 46 | 3.4          | 7.3          | 11      | 31      |           |
| Pazopanib 0, 1, or 2 lines  | 78 | 18.1 weeks   | 50.7 weeks   | 9.5     | 52.7    | 10        |
| Lapatinib 0, 1, or 2 lines  | 74 | 17.1 weeks   | 39.1 weeks   | 5.1     | 48.7    | 10        |
| Sunitinib 0, 1, or 2 lines  | 19 | 3.5          | 0            | 0       | 84.2    | 11        |

**Abbreviations:** mPFS, median progression-free survival; mOS, median overall survival; ORR, objective response rate; DCR, disease control rate; Ref, reference.

**Acknowledgment**

We would like to thank Professor Fengming Kong for her guidance.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

The study is partially supported by funding from Wenzhou Municipal Science and Technology Bureau (2018H0004).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
3. Falchetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2016;11:CD005342. doi:10.1002/14651858.CD011360.pub2
4. Angioli R, Plotti F, Alosi A, et al. A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. *Gynecol Oncol*. 2015;139(3):433–438. doi:10.1016/j.ygyno.2015.09.082

5. Heinzelmann F, Henke G, von Graevenitz M, et al. Adjuvant radio-chemotherapy in patients with locally advanced high-risk cervical cancer. *Strahlenther Onkol*. 2012;188(7):568–575. doi:10.1007/s00066-012-1213-2

6. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. *Gynecol Oncol*. 2012;125(2):307–311. doi:10.1016/j.ygyno.2012.02.009

7. Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. *Clin Ther*. 2016;38(3):449–458. doi:10.1016/j.clinthera.2016.02.007

8. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicity. *Future Oncol*. 2015;11(6):909–922. doi:10.2217/fon.14.276

9. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*. 2014;370(8):734–743. doi:10.1056/NEJMoa1309748

10. Monk BJ, Mas Locer L, Zbarb JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. *J Clin Oncol*. 2010;28(22):3562–3569. doi:10.1200/JCO.2009.26.9571

11. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG trial IND.184. *Gynecol Oncol*. 2010;116(2):163–167. doi:10.1016/j.ygyno.2009.08.012

12. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. *Cancer Sci*. 2011;102(7):1374–1380. doi:10.1111/j.1349-7006.2011.01939.x

13. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. *J Clin Oncol*. 2013;31(26):3219–3225. doi:10.1200/JCO.2013.48.8585

14. Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. *J Clin Oncol*. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.5995

15. Xue JM, Astere M, Zhong MX, Lin H, Shen J, Zhu YX. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. *Onco Targets Ther*. 2018;11:6119–6128. doi:10.2147/OTT.S172717

16. Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. *Onco Targets Ther*. 2018;11:4137–4147. doi:10.2147/OTT.T157717

17. Sun D, Hou H, Zhang C, Zhang X. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. *Onco Targets Ther*. 2018;11:6539–6554. doi:10.2147/OTT.T19043